Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020;9(2):107-113.
doi: 10.3233/JHD-200397.

Irritability in Huntington's Disease

Affiliations
Review

Irritability in Huntington's Disease

Nicholas E Karagas et al. J Huntingtons Dis. 2020.

Abstract

Huntington's disease (HD) is a heritable and fatal neurodegenerative disease characterized by a triad of motor, cognitive and neuropsychiatric symptoms. A common and particularly detrimental neuropsychiatric alteration in HD gene carriers is irritability, which frequently manifests as abrupt and unpredictable outbursts of anger. This symptom increases the burden of HD in multiple ways, such as jeopardizing employment and straining familial or caregiver support. Although irritability in HD is diagnosed by the administration of standardized rating scales and clinical expertise, measurement of severity and progression is complicated by several factors. Currently, individuals with HD who present with irritability may be managed with a variety of psychotropic medications, primarily antidepressants and antipsychotics. While these therapies offer relief to individuals suffering from irritability in HD, they are often not sufficient. Here, we review irritability in the context of HD and emphasize the need for treatments that are better tailored to mitigate this troublesome symptom. An expeditious strategy in pursuit of this goal involves evaluating the efficacy of approved medications that are used to treat similar neuropsychiatric symptoms.

Keywords: Huntington’s disease; behavioral symptoms; irritable mood; neuropsychiatry; psychotropic drugs.

PubMed Disclaimer

Conflict of interest statement

Erin Furr Stimming receives research funding from Roche/Genetech, Cures within Reach, Vaccinex, Uniqure, CHDI and HDSA.

References

    1. McColgan P, Tabrizi SJ. Huntington’s disease: A clinical review. Eur J Neurol. 2018;25(1):24–34. doi: 10.1111/ene.13413. - DOI - PubMed
    1. Wild EJ, Tabrizi SJ. Therapies targeting DNA and RNA in Huntington’s disease. Lancet Neurol. 2017;16(10):837–47. doi: 10.1016/S1474-4422(17)30280-6. - DOI - PMC - PubMed
    1. Ghosh R, Tabrizi SJ. Clinical features of Huntington’s disease. Adv Exp Med Biol. 1049)1–28. doi: 10.1007/978-3-319-71779-1_1. - DOI - PubMed
    1. Martinez-Horta S, Perez-Perez J, van Duijn E, Fernandez-Bobadilla R, Carceller M, Pagonabarraga J, et al. Neuropsychiatric symptoms are very common in premanifest and early stage Huntington’s Disease. Parkinsonism Relat Disord. 2016;25:58–64. doi: 10.1016/j.parkreldis.2016.02.008. - DOI - PubMed
    1. Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, et al. Biological and clinical manifestations of Huntington’s disease in the longitudinal TRACK-HD study: Cross-sectional analysis of baseline data. Lancet Neurol. 2009;8(9):791–801. doi: 10.1016/S1474-4422(09)70170-X. - DOI - PMC - PubMed

MeSH terms